# Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

> **NCT04302454** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 280 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Leuprorelin

## Key facts

- **NCT ID:** NCT04302454
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-19
- **Primary completion:** 2027-10-21
- **Final completion:** 2027-12-01
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2025-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04302454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04302454, "Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04302454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*